Ustecinumab 130 mg/26 ml sol inj fr 26 ml IV e Ustecinumab 90 mg/1 ml sol inj caneta 1 ml SC
TED · 496760-2026Award notice · social & specific servicesawardedNo deadline given
Value
Estimated—
Awarded€953,414 · 953,413.6 EUR
WinnerJanssen Cilag Farmacêutica, Lda
Who already wins at this buyer
Firms with recorded awards from Unidade Local de Saúde de São José, EPE in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| Vertex Pharmaceuticals (Portugal), Unipessoal Lda | 2 | €5,562,837 | 2026-08-07 |
| Roche Sistemas de Diagnósticos, Lda | 2 | €4,637,771 | 2026-08-04 |
| Novo Nordisk, Lda | 2 | €1,931,304 | 2026-08-17 |
| Johnson & Johnson, Lda. | 2 | €1,265,691 | 2026-07-06 |
| Stryker Portugal Produtos Médicos, Lda. | 2 | €869,259 | 2026-08-03 |
Full buyer profile: what Unidade Local de Saúde de São José, EPE buys and who wins it →
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
41005326 - Ustecinumab 130 mg/26 ml sol inj fr 26 ml IV e Ustecinumab 90 mg/1 ml sol inj caneta 1 ml SC
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-09-22 | 2023/0491 - CANACINUMAB [150 MG/ML 1 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-06-09 | 2023/0491 - SECUCINUMAB [300 MG/2 ML SOL INJ CANETA/ SERINGA] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-08-04 | 2023/0491 - SECUCINUMAB [300 MG/2 ML SOL INJ CANETA/ SERINGA] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-09-09 | AMIVANTAMAB 50 MG/ML SOL INJ FR 7 ML IV | Unidade Local de Saúde de São José, EPE PT | 93% |
| 2026-09-23 | Aquisição de UPADACITINIB 30 MG COMP LP e UPADACITINIB 45 MG COMP LP | Unidade Local de Saúde de São José, EPE PT | 92% |
| 2026-05-12 | 2023/0491 - PEMBROLIZUMAB [25 MG/ ML 4 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 92% |